- Home
- REFI vs TLSI Comparison
REFI vs TLSI Comparison
Compare REFI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- TLSI
- Stock Information
- Founded
- REFI 2021
- TLSI 2010
- Country
- REFI United States
- TLSI United States
- Employees
- REFI N/A
- TLSI N/A
- Industry
- REFI Real Estate Investment Trusts
- TLSI Medical Specialities
- Sector
- REFI Real Estate
- TLSI Health Care
- Exchange
- REFI Nasdaq
- TLSI Nasdaq
- Market Cap
- REFI 255.6M
- TLSI 244.3M
- IPO Year
- REFI 2021
- TLSI N/A
- Fundamental
- Price
- REFI $12.85
- TLSI $4.70
- Analyst Decision
- REFI Strong Buy
- TLSI Strong Buy
- Analyst Count
- REFI 3
- TLSI 4
- Target Price
- REFI $20.00
- TLSI $11.13
- AVG Volume (30 Days)
- REFI 137.6K
- TLSI 131.5K
- Earning Date
- REFI 11-04-2025
- TLSI 11-13-2025
- Dividend Yield
- REFI 15.94%
- TLSI N/A
- EPS Growth
- REFI N/A
- TLSI N/A
- EPS
- REFI 1.84
- TLSI N/A
- Revenue
- REFI $56,608,781.00
- TLSI $35,990,000.00
- Revenue This Year
- REFI $11.43
- TLSI $56.71
- Revenue Next Year
- REFI $4.75
- TLSI $52.25
- P/E Ratio
- REFI $7.03
- TLSI N/A
- Revenue Growth
- REFI 2.58
- TLSI 45.50
- 52 Week Low
- REFI $12.00
- TLSI $3.42
- 52 Week High
- REFI $16.29
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- REFI 45.34
- TLSI 45.51
- Support Level
- REFI $12.87
- TLSI $4.87
- Resistance Level
- REFI $13.24
- TLSI $5.18
- Average True Range (ATR)
- REFI 0.21
- TLSI 0.23
- MACD
- REFI 0.05
- TLSI -0.01
- Stochastic Oscillator
- REFI 61.29
- TLSI 44.74
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.